• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down 1.66% Nasdaq Down 1.05%

    Akebia Therapeutics, Inc. (AKBA)

    -NasdaqGM
    7.14 Up 0.56(8.51%) Sep 4, 3:59PM EDT
    Add to Portfolio
    Prev Close:6.58
    Open:6.50
    Bid:N/A
    Ask:10.05 x 100
    1y Target Est:18.17
    Beta:N/A
    Earnings Date:Nov 9 - Nov 13 (Est.)
    Day's Range:6.40 - 7.17
    52wk Range:5.91 - 23.41
    Volume:210,716
    Avg Vol (3m):400,282
    Market Cap:206.22M
    P/E (ttm):N/A
    EPS (ttm):-1.90
    Div & Yield:N/A (N/A)
    Quotes delayed, except where indicated otherwise. Currency in USD.

    Headlines

    » More Headlines for AKBA

    Comparison

    Symbol% ChgMkt Cap
    AKBAUp 8.51%206.22M
    AMGNDown 1.48%111.48B
    JNJDown 1.44%252.85B

    Key Statistics

    Forward P/E (1 yr):N/A
    P/S (ttm):N/A
    Ex-Dividend Date:N/A

    Analysts

    Annual EPS Est (Dec-15) :-2.03
    Quarterly EPS Est (Sep-15) :-0.53
    Mean Recommendation*:2.0
    PEG Ratio (5 yr expected):N/A

    * (Strong Buy) 1.0 - 5.0 (Sell)

    Analyst Opinion | Estimates

    Business Summary

    Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of proprietary therapeutics based on hypoxia inducible factor (HIF) biology for patients with kidney disease. View More
    Your browser doesn't support canvas
    SETTINGS
    Scrolling
    Speed
    Display
    Price
    Submit Feedback